Last updated: September 4, 2026
Ibuprofen lysine is a mature ibuprofen salt with two distinct commercial markets: over-the-counter and prescription oral products, and sterile intravenous ibuprofen lysine injection for premature infants with patent ductus arteriosus. The oral market is price-driven and largely unprotected by meaningful product patents. The neonatal injection market has greater regulatory and manufacturing barriers, but its revenue pool is limited by the small patient population and hospital purchasing controls.
The most commercially relevant branded prescription product is NeoProfen, an ibuprofen lysine injection approved by the U.S. Food and Drug Administration in 2006 for closure of clinically significant patent ductus arteriosus in premature infants. Ibuprofen lysine also appears in oral products sold under regional brands such as Nurofen Express and other rapid-release ibuprofen formulations. Product-level revenue is generally not disclosed separately by manufacturers, preventing a reliable standalone global sales estimate.
What is ibuprofen lysine and how is it used?
Ibuprofen lysine is the lysine salt of ibuprofen. The salt improves aqueous solubility and permits sterile intravenous formulation, while retaining ibuprofen's cyclooxygenase-inhibiting pharmacology.
| Market |
Primary use |
Dosage form |
Commercial profile |
| Neonatal hospital care |
Closure of patent ductus arteriosus |
Intravenous injection |
Small, specialized, higher regulatory barrier |
| Adult and pediatric pain |
Analgesia and fever reduction |
Oral tablets, capsules, sachets, suspensions |
Large, mature, highly competitive |
| Dysmenorrhea and inflammatory pain |
Short-term symptom control |
Oral products |
OTC and pharmacy-led demand |
| Hospital analgesia |
Acute pain and fever |
IV ibuprofen products |
Competes with standard ibuprofen and other NSAIDs |
For NeoProfen, the FDA-approved regimen uses three intravenous doses over three days. The label identifies premature infants weighing 500 to 1,500 grams and gestational age of 32 weeks or less as the core treatment population. The product is administered in neonatal intensive-care settings, where dosing, renal function, bleeding risk, and gastrointestinal safety are closely monitored (FDA, 2023a).
What is the FDA status of ibuprofen lysine?
The FDA approved NeoProfen on July 19, 2006, under New Drug Application 021670. Its indication is closure of clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1,500 grams who are no more than 32 weeks gestational age when medical management is appropriate (FDA, 2023a).
The main FDA-regulated product categories are:
| Product category |
FDA status |
Principal commercial issue |
| NeoProfen injection |
Approved prescription product |
Neonatal hospital demand and generic competition |
| Oral ibuprofen lysine |
Products may be approved or marketed regionally depending on jurisdiction |
OTC substitution and brand competition |
| Standard ibuprofen injection |
Separate products and indications |
Competes in adult hospital analgesia, not necessarily neonatal PDA |
| Compounded neonatal ibuprofen |
Hospital or outsourcing-pharmacy supply |
Quality, sterility, and regulatory scrutiny |
Ibuprofen lysine should not be treated as interchangeable across all products. The active moiety is ibuprofen, but the salt, concentration, route, excipients, labeling, and approved indication affect substitution and regulatory status.
What patents protect ibuprofen lysine and NeoProfen?
The core composition-of-matter protection for ibuprofen is expired. Ibuprofen was commercialized decades ago, and the basic molecule is available from multiple active pharmaceutical ingredient suppliers.
NeoProfen's commercial protection was based primarily on regulatory exclusivity, product-specific patents, formulation know-how, and the difficulty of developing an approved sterile neonatal injectable product. Those protections are materially weaker today than they were at launch.
| Protection layer |
Current position |
| Ibuprofen molecule |
Expired |
| Ibuprofen lysine salt as a broad concept |
No meaningful blocking exclusivity in the mature market |
| Neonatal injectable formulation |
Historical product-specific protection; current blocking value depends on live claims |
| FDA approval exclusivity |
Historical exclusivity has expired |
| Pediatric exclusivity |
Historical six-month extension, if granted, has expired |
| Manufacturing process |
Potentially relevant if privately held or claimed, but generally avoidable through alternative processes |
| Trademark |
Brand protection may remain, but it does not block generic ibuprofen lysine |
A current patent-by-patent freedom-to-operate conclusion requires a live claim-status review in each jurisdiction. Public commercial facts support a more limited conclusion: ibuprofen lysine is not protected by a current, broad, molecule-level patent moat comparable to a recent small-molecule launch.
When does ibuprofen lysine lose exclusivity?
The central U.S. exclusivity dates have already passed.
| Event |
Date or status |
| NeoProfen FDA approval |
July 19, 2006 |
| Expected new-drug exclusivity period |
Expired |
| Potential pediatric exclusivity extension |
Expired, if awarded |
| Current broad ibuprofen patent protection |
Expired |
| Generic-entry environment |
Open or potentially open, subject to product-specific approvals and litigation |
The commercial loss of exclusivity is less important for oral ibuprofen lysine because that market was already dominated by generic and branded OTC products. For the neonatal injection, loss of exclusivity has greater strategic importance because hospitals can shift purchasing to approved generic products or alternative PDA therapies.
What is the Orange Book status of NeoProfen?
The FDA Orange Book is the controlling source for current U.S. patent and exclusivity listings. NeoProfen is identified in FDA drug databases as a prescription product approved under NDA 021670. Historical exclusivity has expired, and any current patent impact must be assessed against the active Orange Book listing rather than the historical approval record (FDA, 2024a).
The practical Orange Book implications are:
- The product is no longer protected by original FDA exclusivity.
- A generic applicant may rely on an abbreviated pathway if an FDA-approved reference product and applicable regulatory conditions support that filing.
- Any listed method-of-use patent may be addressed through a section viii statement or a Paragraph IV certification, depending on the patent and proposed labeling.
- A generic applicant that certifies Paragraph IV may trigger patent litigation under the Hatch-Waxman Act.
No major, publicly visible U.S. litigation campaign has established a durable current barrier to generic ibuprofen lysine injection comparable to the litigation surrounding high-value specialty drugs.
Are there Paragraph IV challenges to ibuprofen lysine?
Paragraph IV risk exists in principle for any listed drug patent that remains active. The commercial significance of that risk for ibuprofen lysine is limited because the principal molecule and the original product exclusivity are old.
A generic applicant challenging a listed patent would typically assert that the patent is invalid, unenforceable, or not infringed. The reference-product sponsor could file an infringement action within 45 days of receiving notice, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework, subject to statutory exceptions and later court developments (Congress, 1984; FDA, 2024b).
The main practical questions are not whether the ibuprofen molecule remains protected. They are whether any formulation, concentration, manufacturing, or method-of-use claims remain listed and enforceable, and whether the generic applicant can meet sterile manufacturing and neonatal labeling requirements.
What formulations are protected by ibuprofen lysine patents?
Formulation protection is more relevant than chemical protection. Potentially valuable claims may cover:
- Sterile aqueous ibuprofen lysine solutions.
- Concentration and pH ranges suitable for intravenous administration.
- Stability during storage and dilution.
- Container-closure systems.
- Low-volume neonatal dosing presentations.
- Manufacturing controls that limit particulate matter, degradation, or microbial contamination.
- Premixed or ready-to-use presentations.
These claims are narrower than a composition-of-matter patent. Competitors can often design around them by changing concentration, excipients, packaging, sterilization parameters, or manufacturing sequence. The economic strength of formulation patents depends on whether the hospital market accepts the alternative product and whether the product can meet neonatal quality standards.
How strong is the ibuprofen lysine patent estate?
The patent estate is weak for broad chemical protection and moderate for specialized sterile delivery.
| Dimension |
Assessment |
| Molecule-level exclusivity |
Very weak; expired |
| Salt-form exclusivity |
Weak in a mature global market |
| Oral formulation protection |
Weak; numerous design-around options |
| Sterile injectable formulation |
Moderate where live claims exist |
| Neonatal indication |
Moderate regulatory and clinical differentiation |
| Manufacturing barrier |
Moderate to high for sterile injectable products |
| Brand loyalty |
Limited in hospital procurement |
| Overall commercial moat |
Low to moderate |
The most durable barrier is operational rather than purely legal. A supplier must maintain validated sterile manufacturing, reliable supply, neonatal dosing accuracy, pharmacovigilance, and hospital contracting. These barriers can delay entry even when patent protection is limited.
Which companies compete with ibuprofen lysine?
Competition differs by indication.
Neonatal patent ductus arteriosus
NeoProfen competes with:
- Intravenous indomethacin.
- Intravenous or oral ibuprofen products approved or used for PDA closure in relevant jurisdictions.
- Acetaminophen, which is used in some clinical settings and may be selected when NSAID-related risks are a concern.
- Surgical or catheter-based PDA closure in selected patients.
Clinical practice is influenced by renal function, platelet effects, gastrointestinal risk, local protocols, drug availability, and physician preference. Ibuprofen and indomethacin are pharmacologically related NSAID options, while acetaminophen is mechanistically different.
Oral analgesia and fever
Oral ibuprofen lysine competes with:
- Standard ibuprofen salts and formulations.
- Paracetamol or acetaminophen.
- Naproxen.
- Aspirin in selected adult markets.
- Ketoprofen and other regional NSAID products.
- Private-label pharmacy and supermarket products.
The principal differentiator for oral ibuprofen lysine is speed of dissolution or perceived onset, not a fundamentally different clinical effect. That benefit is difficult to defend against competing rapid-release formulations.
How does ibuprofen lysine compare with indomethacin and acetaminophen for PDA?
| Attribute |
Ibuprofen lysine |
Indomethacin |
Acetaminophen |
| Drug class |
NSAID |
NSAID |
Analgesic-antipyretic |
| PDA use |
Established in premature infants |
Established in premature infants |
Used in selected settings |
| Renal concerns |
Material |
Material and often prominent |
Different safety profile |
| GI and platelet concerns |
Present |
Present |
Generally different |
| Market maturity |
High |
High |
Increasing clinical use in some settings |
| Patent position |
Mature and weak |
Mature and weak |
Generally weak for the indication |
| Key purchasing factor |
Availability, protocol fit, price |
Availability, protocol fit, price |
Safety profile and local evidence |
Meta-analyses have generally found ibuprofen and indomethacin to have similar PDA closure efficacy, with differences in adverse-event profiles and clinical tolerability. Acetaminophen has expanded the treatment conversation but has not eliminated NSAID use (Ohlsson & Shah, 2020).
What is the financial trajectory for ibuprofen lysine?
The financial trajectory is bifurcated.
Oral ibuprofen lysine
Oral products are mature consumer-health assets. Revenue growth is likely to come from:
- Price increases.
- Geographic expansion.
- Premium rapid-release positioning.
- Brand marketing.
- Pack-size and channel optimization.
- Private-label manufacturing contracts.
Volume growth is constrained by market saturation, generic substitution, and consumer switching among NSAIDs and acetaminophen. Margin pressure is persistent because the active ingredient is inexpensive and manufacturing is widely available.
Neonatal injectable ibuprofen lysine
The neonatal product has a smaller but more defensible revenue pool. Its economics depend on:
- Number of premature births treated.
- Hospital formulary placement.
- Contract pricing.
- Generic competition.
- Supply reliability.
- Product wastage from single-dose or low-volume presentations.
- Reimbursement and hospital budget controls.
The product is unlikely to develop blockbuster economics without a broader approved indication or a significant expansion into adult hospital analgesia. Adult IV ibuprofen is a separate commercial market and does not automatically expand the addressable market for ibuprofen lysine used in neonatal PDA.
Public company filings generally do not disclose NeoProfen revenue separately. Manufacturers report broader segments, brands, or product families. As a result, standalone revenue, gross margin, and market share cannot be validated from issuer disclosures. The financial outlook is best characterized as stable-to-declining for legacy branded neonatal revenue, with offsetting potential from generic volume and specialized hospital supply agreements.
What generic launch scenarios exist for ibuprofen lysine?
Scenario 1: Limited generic entry
One approved generic enters the market and captures a meaningful share through hospital contracts. The branded product retains premium pricing where supply reliability, physician familiarity, or formulary inertia matters.
Scenario 2: Multi-source price compression
Several injectable suppliers enter. Hospital group purchasing organizations use competitive bidding, reducing net prices and compressing branded and generic margins. This is the most likely long-term direction for a mature injectable product if multiple suppliers qualify.
Scenario 3: Supply-constrained duopoly
Only one or two suppliers maintain reliable sterile production. A generic obtains approval but cannot consistently supply hospitals. Prices decline less than expected, and the incumbent retains strategic value through availability.
Scenario 4: Clinical substitution
Hospitals shift some PDA treatment to indomethacin or acetaminophen based on protocols, safety considerations, or procurement economics. Ibuprofen lysine volume declines even without direct generic substitution.
What manufacturing and intellectual-property barriers remain?
Sterile injectable manufacturing is the principal barrier. A supplier must demonstrate:
- Validated aseptic processing or terminal sterilization, where appropriate.
- Control of particulate matter and endotoxins.
- Container-closure integrity.
- Stability across the labeled shelf life.
- Accurate low-volume dosing.
- Consistent active-ingredient concentration.
- Compliance with FDA current good manufacturing practice requirements.
The API itself is not scarce or technically difficult compared with complex biologics. The risk is concentrated in sterile finished-dose manufacturing, quality systems, regulatory inspection, and reliable supply. This creates a higher entry threshold than oral ibuprofen lysine but not a durable barrier equivalent to biologic manufacturing.
What licensing deals affect ibuprofen lysine?
Licensing has historically been more relevant to the branded neonatal product than to oral ibuprofen lysine. The commercial model has included product rights, regional distribution, and portfolio transactions involving specialty or hospital medicines.
Current commercial value depends on the rights package:
| Deal feature |
Effect on value |
| U.S. rights to the approved neonatal product |
Highest value |
| Global rights |
More volume but greater regulatory and supply obligations |
| Manufacturing rights |
Can improve margin and supply control |
| Distribution-only rights |
Lower risk and lower margin |
| Rights including new indications |
Higher strategic value |
| Rights limited to a mature indication |
Primarily cash-flow value |
Because product-level deal economics are generally private, upfront payments, royalties, and milestone obligations should not be inferred without transaction-specific filings or announcements.
What geographic markets are most important?
The United States is strategically important because of the FDA-approved neonatal product and the formal Orange Book and Hatch-Waxman framework. Europe and other markets are more fragmented. Oral ibuprofen lysine has stronger commercial relevance in countries where rapid-release brands are established and consumers pay a premium for perceived faster onset.
Geographic value depends on:
- Local approval of the lysine formulation.
- National treatment protocols for PDA.
- Hospital procurement structures.
- OTC brand strength.
- Local generic penetration.
- Patent and supplementary protection certificate status.
- Availability of licensed sterile manufacturers.
There is no single global exclusivity position. Patent, regulatory, and substitution outcomes must be assessed country by country.
What patent litigation affects ibuprofen lysine?
No broad, high-value patent litigation pattern currently defines the ibuprofen lysine market. The litigation risk is mainly transactional and product-specific:
- Paragraph IV challenges to any remaining listed patents.
- Patent disputes over sterile formulation or packaging.
- Regulatory disputes involving abbreviated applications.
- Manufacturing and supply litigation.
- Trademark disputes involving regional oral brands.
- Product-liability litigation related to neonatal NSAID safety.
The absence of major current litigation does not eliminate risk. It indicates that the economic center of gravity has moved from molecule-level patent enforcement to regulatory execution, manufacturing reliability, and contracting.
Key Takeaways
- Ibuprofen lysine is a mature salt of ibuprofen with limited broad patent protection.
- NeoProfen was FDA-approved on July 19, 2006, for PDA closure in premature infants.
- Original FDA exclusivity and any pediatric extension have expired.
- The oral market is highly competitive, with limited pricing power and substantial generic substitution.
- The neonatal injectable market has stronger manufacturing and regulatory barriers but a small addressable population.
- Formulation, packaging, and sterile manufacturing claims are more relevant than molecule-level patents.
- Paragraph IV risk is possible but does not appear to create a broad current barrier to generic entry.
- Ibuprofen lysine competes with indomethacin and, increasingly in some protocols, acetaminophen for PDA treatment.
- Public companies generally do not disclose standalone NeoProfen or ibuprofen lysine revenue.
- The likely financial path is mature or declining branded revenue, with value concentrated in supply reliability, hospital contracts, and efficient sterile manufacturing.
FAQs About Ibuprofen Lysine Patents and Market Economics
Is ibuprofen lysine the same as ibuprofen?
Ibuprofen lysine is a salt form of ibuprofen. It delivers the same active ibuprofen moiety but may have different solubility, formulation, route, labeling, and product characteristics.
Can a generic manufacturer sell ibuprofen lysine injection without licensing NeoProfen?
A manufacturer may be able to file an abbreviated application or another applicable FDA submission without obtaining a commercial license, provided it satisfies FDA requirements and does not infringe enforceable listed patents.
Does ibuprofen lysine have orphan-drug protection?
The neonatal PDA indication may qualify as a specialized pediatric market, but orphan-drug status and exclusivity must be confirmed from the specific FDA approval record. The existence of a small patient population alone does not establish current orphan exclusivity.
Why is injectable ibuprofen lysine more defensible than oral ibuprofen lysine?
Injectable products require sterile manufacturing, validated low-volume dosing, stability data, regulatory inspection readiness, and hospital supply performance. Oral products have simpler manufacturing and many established substitutes.
Is ibuprofen lysine a high-growth pharmaceutical market?
No. It is a mature market. Growth is more likely to come from selective price increases, premium OTC positioning, geographic expansion, or hospital supply arrangements than from underlying demand expansion.
References
-
Congress of the United States. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.
-
Ohlsson, A., & Shah, P. S. (2020). Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database of Systematic Reviews, 2020(2), CD003481.
-
U.S. Food and Drug Administration. (2023a). NeoProfen (ibuprofen lysine) injection prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024b). Hatch-Waxman amendments and abbreviated new drug applications. FDA.
